Overview

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

Status:
Not yet recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.

Phase:

Phase 1

Details

Lead Sponsor:

NeuroPro Therapeutics, Inc.

Treatments:

Bumetanide